Baxter International Inc.

Baxter Healthcare Sa

Other

University of California

Kenneth E Burhop

David Eugene Pereira

Douglas L Looker

David L Foster

Michael P Doyle

Robert J Przybelski

George Owoo

Izydor Z Apostol

Geoffrey F Lee

Douglas D Lemon

Stephen P Trimble

Jane P Richards

Christopher B Glascock

James C Hartman

Jack E McKenzie

Eric A Brucker

Edwin G Moore

Rekha Nayak

Deepak Tiwari

Michael R Schick

Ton-That Hai

John F Hansbrough

Raluan G Soltero

Steven R Shackford

Daniel J Cole

Moses S Chow

Disclosed are concentrate esmolol injection essentially free from other related esters of esmolol and diluted esmolol compositions. The concentrate esmolol formulation includes from about 25-1000 mg/ml of esmolol and about 1-25% w/v of benzyl alcohol and the combination thereof. The compositions can also be used as multi-dose compositions. The present invention also discloses diluted, ready-to-use compositions of esmolol prepared by dilution of the present invention concentrates. Also disclosed are methods of making and using the ready-to-use compositions of the present invention.

Multi-dose concentrate esmolol with benzyl alcohol

A concentrated esmolol formulation is provided that is distinguishable from a diluted form of the concentrated esmolol formulation.

Colored esmolol concentrate

The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.

Reduced side-effect hemoglobin compositions

Hemoglobin chemically modified to reduce oxygen affinity and prevent dissociation are administered parenterally during resuscitation to patients suffering from burn shock. Such treatment, reduces base deficit, increases cardiac output and mean arterial blood pressure, and improves survival.

Chemically modified hemoglobin for burn shock resuscitation

Administration of low doses of hemoglobin minimizes damage to the myocardium after blockage and significantly reduces reperfusion injury. Hemoglobin exerts a pharmacological effect by increasing perfusion and blocking the molecular events leading to permanent injury following an ischemic episode. Additional benefits include a reduction in the number of post-ischemic arrhythmias, reduction in the incidence of restenosis, and improved contractile function in the area of risk.

Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis

Therapeutic treatment of septic shock comprises administering to an animal stroma-free hemoglobin, typically at a dose ranging from the least amount effective to increase perfusion, up to a dosage of about 2500 milligrams kilograms per of body weight.

Use of hemoglobin to treat septic shock

A method for treating head injury in a mammal is provided. The method comprises administering to a mammal having a head injury an effective amount of a hemoglobin preparation. A preferred hemoglobin for use in the method is diaspirin crosslinked hemoglobin.

Therapeutic use of hemoglobin to treat head injury

A method for treating systemic inflammatory response syndrome in a mammal by administering to the mammal a hemoglobin preparation after the mammal is diagnosed as suffering from systemic inflammatory response syndrome, wherein the systemic inflammatory response syndrome is a condition other than sepsis.

Use of hemoglobin to treat systemic inflammatory response syndrome

Administration of low doses of hemoglobin minimizes damage to the myocardium after blockage and significantly reduces reperfusion injury. Hemoglobin exerts a pharmacological effect by increasing perfusion and blocking the molecular events leading to permanent injury following an ischemic episode.

Therapeutic use of hemoglobin in the treatment of blood vessel blockage

A hemoglobin preparation is administered following subarachnoid hemorrhage to dramatically reduce the tissue area of hypoperfusion and the extent of neuronal damage in the area of hypoperfusion.

Use of cross-linked hemoglobin in treating subarachnoid hemorrhage

A method for improving recovery after surgery or an invasive procedure is provided, including administering a hemoglobin preparation to a patient before surgery or an invasive procedure.

Pretraumatic use of hemoglobin

Administration of stroma-free crosslinked hemoglobin during standard cardiac pulmonary resuscitation procedures enhances return of spontaneous circulation following electrical defibrillation. The difficulty in restoring spontaneous circulation directly correlates with a generally poor prognosis in cases of cardiac arrest. The therapeutic effect of hemoglobin as an adjunct to conventional treatment may thereby improve survival.

Growing community of inventors

Mundelein, IL, United States of America

Kenneth E Burhop